Novum is a contract research organization ("CRO") that provides clinical research, data management, statistical and reporting services to the pharmaceutical and related industries. Novum was founded in 1972 and operates Phase I research facilities with a total of 550 beds in three USA locations. Novum is the second largest CRO in the USA as, measured in bed capacity. Novum averages over 200 Phase I studies performed annually.
Novum maintains a highly-experienced management team and staff with the capabilities to perform a wide range of Phase I clinical trials. Although most Phase I studies are conducted with oral dosage formulations, Novum has developed expertise in performing studies with non-traditional delivery systems such as topical transdermal, nasal, inhaled, rectal, vaginal, and intravenous routes of administration. Novum is the world leader in vasoconstrictor studies of topical corticosteroids for both generic and innovator drugs. Further, we are a leader in performing pharmocokinetic (PK), irritation, sensitization, and adhesion studies with transdermal and topical dosage forms.
Novum’s rapidly growing clinical trials management and data management groups, currently focus on performing Phase II through IV clinical endpoint studies requiring large patient populations in non-serious disease states that are treated in an outpatient setting. Examples would include for example many dermatological diseases, allergies, vaccines and diabetes.